Identifying an Early Improvement Cutoff in Psoriasis Area and Severity Index for Outcome Prediction Across Systemic Treatments
Dermatologic Therapy · 2026-01 · 2026 (1)
DOI: 10.1155/dth/6867179 ↗Abstract
Background Early identification of treatment response is clinically important in psoriasis management, as it may facilitate timely treatment modification and reduce exposure to ineffective therapies. Although early improvement in the Psoriasis Area and Severity Index (PASI) has been associated with long‐term outcomes for individual therapies, a broadly applicable early PASI threshold across different treatment modalities in real‐world practice remains unclear. Objectives To evaluate the predictive value of early PASI improvement for subsequent PASI90 achievement across multiple psoriasis treatment modalities and to identify a clinically meaningful early PASI response threshold. Methods This prospective, multicenter real‐world cohort study (approval no. 2020‐36) included adult patients with moderate‐to‐severe plaque psoriasis receiving methotrexate, phototherapy, interleukin (IL)‐17 inhibitors, or IL‐23 inhibitors. Receiver operating characteristic (ROC) curve analyses were used to evaluate the predictive performance of week‐4 PASI improvement for achieving PASI90 at 3 and 6 months. The optimal early response threshold was identified using the Youden Index. Multivariable logistic regression analyses were conducted to assess the independent association between early PASI response and subsequent PASI90 achievement. Results A total of 2023 patients were included in the analysis. The optimal week‐4 PASI improvement threshold for predicting PASI90 at 3 months was 62% for IL‐17 inhibitors, 62% for IL‐23 inhibitors, 59% for methotrexate, and 61% for phototherapy. Multivariable logistic regression analyses further demonstrated that a PASI improvement of approximately 60% at Week 4 was independently associated with a higher likelihood of achieving PASI90 at 3 months. Conclusions Achieving PASI60 at Week 4 serves as a consistent early indicator of subsequent PASI90 response across multiple psoriasis treatment modalities. These findings suggest that PASI60 may represent a potentially generalizable early‐response threshold; however, external validation in independent populations is required before its incorporation into routine clinical decision‐making. Trial Registration: Chinese Clinical Trial Registry: ChiCTR2000036186
EUVIMED